Position history for UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's holdings in RECURSION PHARMACEUTICALS IN
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds 4.1M shares of RXRX (RECURSION PHARMACEUTICALS IN), worth $16.7M as of 2025-Q4. The position was decreased (-2.9% shares). RXRX represents 0.0% of UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's portfolio.
Current Value
$16.7M
Current Shares
4.1M
Total Value Change
+$935,102
Total Shares Change
+2M
Other major holders of RXRX: BNP PARIBAS FINANCIAL MARKETS, BAILLIE GIFFORD & CO, DnB Asset Management AS
Decreased |
| 4.1M |
-2.9% |
| $16.7M |
| 0.0% |
| $4.11 |
0 |
| 2025-Q3 | Decreased | 4.2M | -9.1% | $20.5M | 0.0% | $4.91 | 0 |
| 2025-Q2 | Decreased | 4.6M | -28.0% | $23.4M | 0.0% | $5.03 | 0 |
| 2025-Q1 | Increased | 6.4M | +183.7% | $33.9M | 0.0% | $5.81 | 47 |
| 2024-Q4 | Increased | 2.3M | +5.5% | $15.3M | 0.0% | $6.77 | 30 |
| 2024-Q3 | Increased | 2.1M | +2.0% | $14.1M | 0.0% | $6.98 | 29 |
| 2024-Q2 | Increased | 2.1M | +919.4% | $15.7M | 0.0% | $7.50 | 45 |